Clinical Trial Update: Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant bempegaldesleukin plus nivolumab versus nivolumab alone after complete resection of melanoma at high risk of recurrence was te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Bempegaldesleukin (bempegaldesleukin)
• nivolumab (nivolumab)

Snippet

Sponsor: Nektar Therapeutics | Conditions: Melanoma, Melanoma Stage III | Phase 3 | Status: TERMINATED | Results posted: 2023-04-21